IPO Pipeline Overview - As of August 17, 2025, there are 296 companies in the IPO pipeline, with 28 on the Shanghai Main Board, 37 on the Sci-Tech Innovation Board, 25 on the Shenzhen Main Board, 29 on the Growth Enterprise Market, and 177 on the Beijing Stock Exchange [1] IPO Application Status - The total number of applications processed includes 6 accepted, 237 in inquiry, 14 approved, 23 suspended, and 16 registered [2] Newly Listed Companies - During the period from August 11 to August 17, 2025, two companies were newly listed: Guangdong Academy of Building Research Group Co., Ltd. closed at 34.01 CNY per share with a 418.45% increase and a trading volume of 19.048 billion CNY, while Zhigao Machinery Co., Ltd. closed at 57.66 CNY per share with a 231.19% increase and a trading volume of 1.083 billion CNY [3] New Counseling Records - Four companies received new counseling records: Zhejiang Ouno Machinery Technology Co., Ltd., Jiangsu Handian Biotechnology Co., Ltd., China Aerospace Technology Co., Ltd., and InnoCon Medical Technology (Suzhou) Co., Ltd. [4][5] Approval for Listing - Three companies successfully passed the review process: Zhejiang Kema Friction Materials Co., Ltd., Xi'an Yisiwei Material Technology Co., Ltd., and Harbin Itama Dapeng Industrial Co., Ltd. [6][7][8] Registration Approval - Three companies received registration approval: Zhejiang Jinhua New Materials Co., Ltd., Daoshengtianhe Material Technology (Shanghai) Co., Ltd., and Marco Polo Holdings Co., Ltd. [9] Termination of Review - Only Wuxi Sunshine Precision Machinery Co., Ltd. withdrew its IPO application during this period [10]

Core Viewpoint - UBS has added Kangfang Biotech (09926) to its list of major recommended stocks in the Asia-Pacific region, citing that the overseas potential of its main asset, Edafo, is not fully reflected in the stock price [1] Group 1: Company Analysis - UBS believes that reports of potential collaborations with multinational companies and the upcoming HARMONi study presentation at the 2025 World Lung Cancer Congress will serve as positive catalysts for the stock price [1] - The target price for Kangfang Biotech has been raised from HKD 197.5 to HKD 224.3, with a "Buy" rating assigned [1] - The valuation of Kangfang Biotech is approximately at the median of the biotech stocks covered by UBS, indicating potential for further outperformance [1] Group 2: Sales Forecasts - UBS has increased its peak sales estimate for Edafo from USD 14.6 billion to USD 16.3 billion [1] - The peak sales estimate for another key asset, Kantani, has been raised from USD 2.2 billion to USD 3.4 billion [1]

Market Overview - The Hang Seng Index closed at 25,270.07 points, down 0.98% for the day and up 25.97% year-to-date[5] - The Technology Index decreased by 0.59%, with a year-to-date increase of 24.06%[5] - The Financial Index fell by 1.25%, with a year-to-date increase of 10.29%[5] Corporate Earnings - Kingdee International's interim loss narrowed by 55.14% to approximately 97.74 million RMB, driven by a 22.1% year-on-year revenue growth in cloud subscription services[15] - Kingsray Biotech reported a loss of 25.46 million USD for the interim period, compared to a loss of 175 million USD in the same period last year[7] Investment Insights - Tencent Holdings (700.HK) has a target price of 550 HKD, with a suggested buy price of 480 HKD, currently trading at 554 HKD[11] - Kingdee International (268.HK) is recommended for purchase at 15.4 HKD, with a target price of 17 HKD, currently at 15.96 HKD[15] Economic Indicators - The Hong Kong Monetary Authority reported that 75% of banks are adopting AI, with 90% of positions requiring relevant skills[2] - The U.S. 10-year Treasury yield is at 4.3082%, reflecting a year-to-date decrease of 26.08 basis points[24] Market Trends - The report indicates a potential for further adjustments in the Hong Kong stock market due to ongoing deflationary pressures in mainland China and signs of inflation rebound in the U.S.[9] - The average trading volume in the Hong Kong market decreased by 15.8% to 312.687 billion HKD[7]

Core Viewpoint - UBS has added Kangfang Biopharma to its list of major recommended stocks in the Asia-Pacific region, believing that the overseas potential of its key asset, Edafo, is not fully reflected in its stock price [1] Group 1: Company Potential - UBS highlights that reports of potential collaborations with multinational companies and the upcoming HARMONi study presentation at the 2025 World Lung Cancer Congress serve as positive catalysts for the stock price [1] - The company is also advancing the global registration and research of another key asset, Okanani [1] Group 2: Financial Estimates - UBS has raised its peak sales forecast for Edafo from $14.6 billion to $16.3 billion and for Okanani from $2.2 billion to $3.4 billion [1] - The target price for Kangfang Biopharma has been increased from HKD 197.5 to HKD 224.3, maintaining a "Buy" rating [1]

Market Performance - The China Securities Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index increased by 1.5% [1] - The Hang Seng Hong Kong Stock Connect Innovative Drug Index rose by 1.3% [1] - The China Securities Biotechnology Theme Index and the China Securities Innovative Drug Industry Index both saw an increase of 0.7% and 0.5% respectively [1] - The CSI 300 Pharmaceutical and Health Index grew by 0.6% [1] - The Hang Seng Innovative Drug ETF (159316) experienced a net subscription of 18 million units, reaching a record high of 1.26 billion yuan [1] Index Details - The Biotechnology ETF tracks the China Securities Biotechnology Theme Index, which focuses on leading A-share biotechnology companies involved in gene diagnosis, biopharmaceuticals, blood products, and other human biotechnology [4] - The rolling price-to-earnings (P/E) ratio for the Biotechnology Theme Index is 55.3 times, with a valuation percentile of 0.7% [5] - The Pharmaceutical ETF tracks the CSI 300 Pharmaceutical and Health Index, covering major companies in the pharmaceutical and health sector, including chemical pharmaceuticals, medical services, and medical devices [6][7] - The rolling P/E ratio for the CSI 300 Pharmaceutical and Health Index is 30.7 times, with a valuation percentile of 45.7% [7] ETF Characteristics - The Hang Seng Innovative Drug ETF is the only ETF tracking the innovative drug index, with a low management fee of 0.15% per year and a custody fee of 0.05% per year [9]

Market Performance - The Hang Seng Index opened 197 points lower and closed 249 points or 1% down at 25,270, with a daily trading volume up over 15% to HK$312.687 billion [1] - The Shanghai Composite Index rose 30 points or 0.8% to 3,696, with a turnover of RMB960.6 billion; the Shenzhen Component Index rose 183 points or 1.6% to 11,634, with a turnover of RMB1.28 trillion; the ChiNext Index rose 64 points or 2.6% to 2,534, with a turnover of RMB652.2 billion [2] - The Dow Jones Industrial Average rose 34 points or 0.1% to 44,946; the S&P 500 Index fell 18 points or 0.3% to 6,449; the Nasdaq Composite Index fell 87 points or 0.4% to 21,622 [2] Central Bank Operations - The People's Bank of China conducted a 7 - day reverse repurchase operation worth RMB238 billion at an unchanged rate of 1.4% on the 15th, with a net injection of RMB116 billion after RMB122 billion of reverse repurchases matured. It also carried out a 6 - month buy - out reverse repurchase operation worth RMB500 billion [2] - The central parity rate of the RMB against the US dollar was lowered by 34 points to 7.1371 [2] Corporate News - Huahong Semiconductor is planning to acquire the controlling stake of Shanghai Huili Microelectronics by issuing shares and paying cash, and is currently in contact with potential transaction parties [4] - Argo Biopharma is considering an IPO in Hong Kong, aiming to raise about US$300 million (equivalent to about HK$2.34 billion) [4] - China Shenhua plans a mid - 2025 profit distribution, with the amount not less than 75% and not more than the attributable net profit to shareholders in the first half of the year [4] - Longfor Group issued a profit warning, expecting a 45% drop in profit and a 70% drop in core profit for the six months ended June compared to last year due to the decline in the real estate industry [5] - China Hongqiao reported a 10.1% year - on - year increase in revenue to RMB81.039 billion and a 35% increase in net profit to RMB12.361 billion for the six months ended June, with no interim dividend [5] - Sands China reported a 23.7% year - on - year drop in net profit to US$413 million for the six months ended June, with an interim dividend of HK$0.25 [5] International News - US President Trump and Russian President Putin met in Alaska but did not reach a consensus on a cease - fire in Ukraine. Trump said they discussed land transfer and security guarantees in Ukraine and were close to an agreement, pending Ukraine's approval [3] - Based on the results of the meeting, Trump said he did not think it was necessary to take action regarding China's purchase of Russian oil for the time being and might reconsider in two to three weeks [3] Banking Data - In the first half of 2025, commercial banks in China achieved a cumulative net profit of RMB1.2 trillion. At the end of the second quarter of 2025, the average return on capital was 8.19% and the average return on assets was 0.63% [4]

Financial Performance - The Group's revenue from continuing operations reached $518.8 million, marking an impressive 81.9% year-over-year increase compared to H1 2024[5,65] - Adjusted net profit from continuing operations soared to $178.0 million, a substantial 509.6% increase compared to the $29.2 million in H1 2024[5,65] - GenScript revenue increased by 11.3% to $247.6 million[65,67] - ProBio experienced significant growth, with revenue reaching $246.9 million, a 511.1% increase[5,65,70] - Bestzyme's revenue grew by 8.4% to $28.3 million[65,73] GenScript Highlights - GenScript served over 42,000 customers in H1 2025, up from 39,000+ in H1 2024[18] - The number of scientific journals citing GenScript increased to over 112,000, compared to 100,000+ in H1 2024[18] - R&D functions account for approximately 10% of the 5700+ employees globally[6] ProBio Highlights - ProBio's cash position is $371.1 million[70] - 20 CDMO projects in H1 2025, with >50% from global customers[42] Bestzyme Highlights - Bestzyme's R&D expenses increased by 62%, from $2.9 million in H1 2024 to $4.7 million in H1 2025[59] - International revenue contribution increased, accounting for 23% of revenue in H1 2025 compared to 21% in H1 2024[73] Guidance - The company revised its revenue growth target for FY 2025 from 10%-15% to 13%-15%[78] - Bestzyme expects 20%-25% revenue growth with Adjusted GPM ~45%[78]

Group 1 - The core point of the article highlights the successful transplantation of genetically modified islet cells in a patient with type 1 diabetes, restoring his ability to produce insulin autonomously, marking a significant advancement in gene editing technology [1] - This gene editing technique, particularly using CRISPR, has rapidly developed and expanded its application from single-gene hereditary diseases to over 6,000 diseases, indicating a growing trend in human gene therapy [1] - If this therapy is successfully promoted, it could fundamentally change the management of type 1 diabetes, alleviating the burden of daily insulin injections and frequent blood sugar monitoring for patients [1] Group 2 - Related A-share concept stocks include Beirui Gene and Guanhao Biological [2]

Group 1 - The social security system is transforming from a simple safety net into a robust buffer against risks, supporting China's economic transition amid challenges like weak exports, high local debt, and aging population [1] - The dynamic adjustment mechanism of social security rates is crucial for fostering innovation, as evidenced by a biotech company reducing labor costs by 5% while increasing research positions by 14% due to policy incentives [3] - The social security fund is exploring innovative paths to address hidden debts through equity investments, with pilot projects in affordable housing REITs yielding a 6.8% annual return while absorbing 111,200 units of inventory [4] Group 2 - The cross-provincial adjustment mechanism of unemployment insurance is becoming vital in the context of industrial restructuring, with the central adjustment fund ratio increasing from 3% to 5% to enhance labor market fluidity [6] - The national coordination of social security is a systematic upgrade of risk hedging mechanisms, with a focus on efficient fund utilization in housing construction through special government bonds [9] - The upgrade of the social security system is emerging as a new logic for China's economic development, acting as both a stabilizer for society and a catalyst for economic transformation [10]

Report Title - "Science and Technology Sector Rallies, Fund Segments Rise Steadily - Fund Market Tracking 2025.08.15" [2] Report Industry Investment Rating - Not provided in the report Core Viewpoints - The A-share market strengthened overall, with large, medium, and small-cap representative indices rising over 2%. The growth style was prominent, up 5.0%. Most sectors posted positive returns, with the science and technology sector surging significantly and the banking sector experiencing a notable pullback [6]. - In the fund market, the median return of common stock funds was the highest at 3.6% this week, while international (QDII) alternative investments had the lowest return at -0.5% [6]. - Active equity funds in various sectors rose sharply following the stock market. TMT sector funds led the gains, with a 6.2% increase this week, driving the year-to-date return above 20%. Small and medium-cap and high-valuation stocks showed obvious advantages [6]. - Event-driven private funds had the highest return this year, reaching 27.2% [4]. Summary by Directory 1. This Week's Market Fluctuations 1.1 Performance of Major Asset Classes - The A-share market strengthened, with the CSI 1000 rising 4.1%. The growth style led with a 5.0% increase. Bonds slightly declined, while convertible bonds rose 1.6% driven by the stock market. Hong Kong stocks rose 1.1%, and US stocks rose 0.9%. Gold declined, while other representative commodities rose [9][10]. 1.2 Performance of Industry Themes - Most sectors posted positive returns. The science and technology sector rallied, with sub - industries rising over 5%, and 5G communication and artificial intelligence up over 9%. The pharmaceutical and biological sector also had high gains, with biotech and innovative drugs approaching 4%. The banking sector pulled back 3.2%, and some sub - industries in the cyclical sector declined [13]. 1.3 Performance of Concept Indices - The top five rising concepts were stock trading software, PEEK materials, servers, optical modules (CPO), and liquid - cooled servers, with stock trading software rising 21%. The top five falling concepts were CSSC system, bank selection, central state - owned banks, gold and jewelry, and aircraft carriers, with the CSSC system falling 3.5% [16]. 1.4 Trading Heat Tracking - The top five concepts with the highest trading heat were state - owned enterprise comprehensive, fund heavy - holdings, core assets, specialized and sophisticated small and medium - sized enterprises, and Huijin holdings. The average daily trading volume of state - owned enterprise comprehensive reached 52.49 billion shares. Compared with last week, the top five concepts with rising heat were stock trading software, semiconductor equipment, servers, equal - weighted securities firms, and lithium mines; the top five with falling heat were CSSC system, aircraft carriers, dairy, three - child policy, and SPD [20][21]. 2. Active Equity Fund Tracking 2.1 Classification Returns and Rising Ratios - In the past week, the median return of common stock funds was the highest at 3.6%, and international (QDII) alternative investments had the lowest return at - 0.5%. In the past month, the median return of common stock funds was the highest at 8.3%, and international (QDII) alternative investments had the lowest return at - 0.4%. The highest rising ratio in the past month was for international (QDII) bond funds at 100.0%, and the lowest was for enhanced index bond funds at 0.0%. The lowest maximum drawdown in the past month was for short - term pure bond funds at - 0.1%, and the highest was for international (QDII) alternative investments at - 4.2% [26]. 2.2 Returns of Sub - Labels - From a sector perspective, TMT sector funds rose 6.2% this week, driving the year - to - date return above 20%. Mid - stream manufacturing and pharmaceutical sector funds also rose over 4%. From a style perspective, small - and medium - cap and high - valuation stocks had obvious advantages [28][29]. 2.3 Fund Differentiation within Sectors - In the past week, the Hong Kong stock sector had the lowest differentiation with a return range of 8.9%, and the mid - stream manufacturing sector had the highest with a return range of 21.7%. In the past month, the Hong Kong stock sector had the lowest differentiation with a return range of 18.2%, and the balanced sector had the highest with a return range of 34.9% [31]. 2.4 Fund Differentiation within Styles - In the past week, the low - profitability - quality style had the lowest differentiation with a return range of 17.0%, and the balanced - market - cap and low - growth styles had the highest with a return range of 22.8%. In the past month, the low - profitability - quality style had the lowest differentiation with a return range of 27.8%, and the high - growth and high - quality styles had the highest with a return range of 39.3% [34]. 2.5 Top - Performing Funds in Each Sector - The report lists the top five funds in each sector by return in the past month [38][39]. 2.6 Top - Performing Funds in Each Style - The report lists the top five funds in each style by return in the past month [41]. 3. Private Placement Market Performance 3.1 Overall Performance of the Private Placement Market - Event - driven private funds had the highest return this year, reaching 27.2% [45]. 3.2 Returns of Various Private Placement Types - Stock - strategy private funds: Most high - return products were stock subjective long - only, with year - to - date returns mostly in the 0% - 20% range [48]. - Bond - strategy private funds: Most high - return products were bond composites, with year - to - date returns mostly in the 0% - 5% range [51]. - Portfolio - fund - strategy private funds: All high - return products were FOFs, with year - to - date returns mostly in the 5% - 10% range [55]. - Money - market - strategy private funds: All high - return products were trust products, with year - to - date returns mostly in the 0% - 2% range [58]. - Managed - futures private funds: Most high - return products were based on program trading strategies, with year - to - date returns mostly above 10% [61]. - Relative - value - strategy private funds: Most high - return products were stock - market neutral, with year - to - date returns mostly in the 0% - 10% range [65]. - Macro - strategy private funds: Only three products announced net values this week, and the product of Kua Ke Asset Management had the highest return [69]. - Composite - strategy private funds: Most high - return products were trust products, with year - to - date returns mostly in the 10% - 20% range [72]. - Other - strategy private funds: Most high - return products were under foreign - trade trusts, with year - to - date returns mostly in the 0% - 10% range [75].